Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA accepts Critical Therapeutics asthma drug for review
The company submitted the application in late July and, pending regulatory approval, expects to launch zileuton CR in the second half of 2007. The new drug application includes
The company submitted the application in late July and, pending regulatory approval, expects to launch zileuton CR in the second half of 2007. The new drug application includes
Under the terms of the agreement, Lilly will acquire all of the outstanding shares of Icos common stock at a price of $32 per share. The move by
The designation was granted for the use of Genasense for patients with stage IV malignant melanoma. Orphan drug designation is intended to facilitate the development of drugs that
An investigational new drug application was filed in September 2006 with the FDA for MEM 3454. The FDA has advised the company that it needs more explanation for
The study was authored by UCSF and Rush University Medical Center. CERE-120 carries the gene for neurturin, a naturally occurring protein, whose role is to keep dopamine-secreting neurons
The agreement includes InterMune's lead compound ITMN-191, which is expected to enter clinical trials before the end of the year. The companies will also collaborate on a research
LX2931 is a small molecule compound with potential application in the treatment of diseases such as multiple sclerosis and rheumatoid arthritis. In preclinical research, LX2931 significantly reduced inflammatory
The study will evaluate the safety and preliminary anti-tumor activity of Interleukin 21 (IL-21) in combination with Nexavar. “Our preclinical data have demonstrated that IL-21 can be additive,
The two companies have also signed a settlement agreement which will become effective as of now. The agreement is consistent with the terms previously disclosed by the parties
Inovio will acquire the rights to agreements Valentis made with IDM Pharma, Innogenetics and Pharmexa. Innogenetics and Pharmexa are currently conducting separate phase I trials of DNA vaccines